U.S. Supreme Court Rejects Attempt to Limit Access to Abortion Pill

Mifepristone, which the Food and Drug Administration has approved for up to 10 weeks gestation, is used in about 63% of U.S. abortions.

Jun 13, 2024 at 11:46 am
Justice Brett Kavanaugh wrote the opinion in the united ruling from the Supreme Court, with Justice Clarence Thomas writing a concurring opinion.
Justice Brett Kavanaugh wrote the opinion in the united ruling from the Supreme Court, with Justice Clarence Thomas writing a concurring opinion. Photo: Bill Oxford

The U.S. Supreme Court ruled in a much-anticipated decision Thursday that mifepristone, one of two pharmaceuticals used in medication abortion, can remain available under current prescribing guidelines.

The high court unanimously rejected attempts by anti-abortion groups to roll back access to what was in place more than eight years ago, writing that they lacked standing to bring the case.

Those limits would have made it more difficult for patients to get a prescription for mifepristone, which the Food and Drug Administration has approved for up to 10 weeks gestation and is used in about 63% of U.S. abortions.

Justice Brett Kavanaugh wrote the opinion in the united ruling from the Supreme Court, with Justice Clarence Thomas writing a concurring opinion.


This story was originally published by the Kentucky Lantern and republished here with permission.